PROF NASDAQ
Credit Risk of going bust: lower than 52% of companies Debt: 3.5% of company value Bonds: none of note held by US funds details ▾
Total debt $7.3M against a stock market value of $202.8M.
Distance to default 5.31 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.5M (short-term plus half of long-term), stock volatility 69.9%; Altman Z'' -10.02. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Mississauga, ON L4W 5K5
CA
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids â including through non-invasive methods â and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
-logo-1200x675.PNG?v=20210211152252){kind=logo}
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Menawat Arun Swarup | P-Purchase | 12,027 | $4.73 | 2025-05-16 |
| Menawat Arun Swarup | P-Purchase | 10,003 | $4.33 | 2025-05-15 |
| HOFER MICHAEL | S-Sale | 40,000 | $0.16 | 2012-12-20 |
| HOFER MICHAEL | P-Purchase | 40,000 | $0.15 | 2012-12-18 |
| TEJADA FRED | P-Purchase | 500,000 | $0.00 | 2012-06-19 |